An Innovative Medicines Initiative (IMI) Project for Precision Medicine in Diabetic Kidney Disease
with Lipotype as project partner
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership funded by the Innovative Medicines Initiative (IMI), member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland has announced the launch of a 5-year project (total budget 28.9 Million Euro) with the aim to improve prevention and management of Diabetes Kidney Disease (DKD).
Leading experts from 21 academic institutions, 6 EFPIA pharmaceutical companies, 1 biotech company and JDRF launched BEAt-DKD to provide a holistic systems medicine view of the pathogenesis and heterogeneity of DKD, with the goal to identify targetable mechanisms and pathways underlying initiation and progression of DKD, as well as to identify and validate biomarkers of disease progression and treatment responses, representing first steps towards precision medicine in DKD. Lipotype is project partner in this consortium.
Please download the official press release of the BEAt-DKD consortium here